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Atrial fibrillation (AF), with an extremely
highly age-dependent prevalence, is a most
frequent type of sustained arrhythmia in
the clinic both in developing and devel-
oped countries (Dobrev and Nattel, 2011).
AF patients have a lot of symptoms includ-
ing palpitations, dizziness, breathlessness,
and chest pain. AF will lead to an increased
risk of stroke and aggravate congestive
heart failure (Shi et al., 2013). Compared
with familial AF, the non-familial AF occu-
pies the majority of AF. In China, at
least 10 million people are affected by
it. Therefore, AF is associated with a
remarkable morbidity and mortality, lead-
ing to a large socio-economic burden.
Unfortunately, the underling mechanisms
of AF are still exclusive (Wang et al., 2011;
Liu et al., 2012a,b).
Several hypotheses have been proposed
for AF. Focal activity, single-circuit reen-
try, and multiple-circuit reentry have been
generally considered as three classic mod-
els for AF. In addition, different sub-
strates which facilitate the formation of
AF have also been revealed including elec-
trical remodeling, structure remodeling,
and intracellular Ca2+ handling remodel-
ing. Moreover, various genetic mutations
such as chromosomal loci (10q22-q24 and
6q14-16) mutations, ion channel (Ka+
and Na+) mutations, connexin (GJA5 and
GJA1) mutations in the familial AF and
more recently several common variants
on 4q25, 16q22, and 1q21 in the non-
familial AF have been identified (Xiao
et al., 2011a,b; Liu et al., 2012a,b). Despite
this, the definitive elucidation of AF still
remains relatively limited and unclear
(Zhang et al., 2011).
MicroRNAs (miRNAs, miRs) are a
novel class of endogenous non-coding
RNAs of around 22 nucleotides in length,
which are widely accepted to possess a
key role in the gene expression regulatory
network at the post-transcriptional level
(Wang et al., 2011; Fu et al., 2013). So far,
at least one thousand miRNAs have been
identified and they have been reported
to participate in many fundamental bio-
logical processes including cell prolifer-
ation, growth, differentiation, apoptosis,
and tissue remodeling. Dysregulated miR-
NAs have been shown to be related to the
genesis of many cardiovascular diseases,
including arrhythmia, hypertrophy, and
heart failure. Moreover, miRNAs have also
been identified to be necessary for the dif-
ferentiation of human-derived cardiomy-
ocyte progenitor cells (Xiao et al., 2012).
Furthermore, circulating miRNAs can also
be served as promising biomarkers for
acute myocardial infarction and heart fail-
ure etc. (Dimmeler and Zeiher, 2010; Li
et al., 2013). Thus, it is not surprising
that miRNAs gain a critical position in
the physiological and pathological pro-
cesses of the cardiovascular system (Wang
et al., 2011; Xiao et al., 2011a,b; Liu et al.,
2012a,b).
Several studies have presented inter-
esting connections between miRNAs and
AF. Of note, a group of miRNAs has been
identified to regulate target genes encoding
cardiac ion channels/transporters/Ca2+-
handling proteins, which may participate
in the genesis of AF (Wang et al.,
2011; Dobrev, 2012). Interestingly, many
available data have demonstratedthatmiR-
1, miR-21, miR-26, miR-29, miR-30,
miR-133, miR-208, miR-328, miR-499,
and miR-590 might take part in the gen-
esis of AF (Dawson et al., 2013; Shi et al.,
2013). Most of these miRNAs promote
the electrical or structural remodeling in
the atrium. MiR-26 family contributes
to AF via repressing the expression of
KCNJ2/Kir2.1/IK1 while miRNA-1 via reg-
ulating IK1 expression and Ca2+ handling
proteins. In addition, miR-499 regu-
lates KCNN3/SK3 while miR-328 targets
CACNA1C and CACNB, contributing to
adverse electrical remodeling (Lu et al.,
2010). Moreover, miR-133 and miR-590
have been found to target transforming
growth factor-β1 (TGF-β1) and TGF-
β receptor type II (TGF-βRII), leading
to structure remodeling in AF (Shan
et al., 2009). Interestingly, circulating lev-
els of miR-328 and miR-150 have been
reported to be down-regulated in AF
patients though the functional role is still
unclear (Liu et al., 2012a,b; McManus
et al., 2014).
With more systematic and insightful
studies exploring the miRNAs basis for
AF, novel therapeutics will be developed
and ultimately lead to advanced treatment
(Zhao et al., 2013).
ACKNOWLEDGMENTS
This work was supported by the
grants from National Natural Science
Foundation of China(81200169 to Junjie
Xiao), Innovation Program of Shanghai
Municipal Education Commission
(13YZ014 to Junjie Xiao), Foundation for
University Young Teachers by Shanghai
Municipal Education Commission
(year 2012, to Junjie Xiao), Innovation
www.frontiersin.org April 2014 | Volume 5 | Article 97 | 1
Fu et al. MicroRNA as a novel player in atrial fibrillation
Foundation of Shanghai University
(sdcx2012038, to Junjie Xiao).
REFERENCES
Dawson, K., Wakili, R., Ördög, B., Clauss, S., Chen,
Y., Iwasaki, Y., et al. (2013). MicroRNA29:
a mechanistic contributor and potential
biomarker in atrial fibrillation. Circulation
127, 1466–1475, 1475e1–1475e28. doi: 10.1161/
CIRCULATIONAHA.112.001207
Dimmeler, S., and Zeiher, A. (2010). Circulating
microRNAs: novel biomarkers for cardiovascular
diseases? Eur. Heart J. 31, 2705–2707. doi: 10.1093/
eurheartj/ehq221
Dobrev, D. (2012). Is altered atrial microRNA-ome
a critical contributor to the pathophysiology of
atrial fibrillation? Basic Res. Cardiol. 107, 284. doi:
10.1007/s00395-012-0284-2
Dobrev, D., and Nattel, S. (2011). New insights
into the molecular basis of atrial fibrilla-
tion:mechanistic and therapeutic implications.
Cardiovasc. Res. 89, 689–691. doi: 10.1093/cvr/
cvr021
Fu, S., Zhuo, R., Yao, M., Zhang, J., Zhou, H., and
Xiao, J. (2013). MicroRNA basis of physiologi-
cal hypertrophy. Front. Genet. 4:253. doi: 10.3389/
fgene.2013.00253
Li, J., Xu, J., Cheng, Y., Wang, F.,Song, Y., and Xiao,
J. (2013). Circulating microRNAs as mirrors of
acute coronary syndromes: MiRacle or quagMire?
J. Cell. Mol. Med. 17, 1363–1370. doi: 10.1111/
jcmm.12148
Liu, X., Wang, F., Knight, A., Zhao, J., and Xiao, J.
(2012a). Common variants for atrial fibrillation:
results from genome-wide association studies.
Hum. Genet. 131, 33–39. doi: 10.1007/s00439-011-
1052-3
Liu, Z., Zhou, C., Liu, Y., Wang, S., Ye, P., Miao,
X., et al. (2012b). The expression levels of plasma
micoRNAs in atrial fibrillation patients. PLoS ONE
7:e44906. doi: 10.1371/journal.pone.0044906
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang,
F., et al. (2010). MicroRNA-328 contributes to
adverse electrical remodeling in atrial fibrilla-
tion. Circulation 122, 2378–2387. doi: 10.1161/
CIRCULATIONAHA.110.958967
McManus, D. D., Lin, H., Tanriverdi, K., Quercio,
M., Yin, X., Larson, M. G., et al. (2014). Relations
between circulating microRNAs and atrial fibrilla-
tion: data from the framingham offspring study.
Heart Rhythm. 11, 663–669. doi: 10.1016/j.hrthm.
2014.01.018
Shan, H., Zhang, Y., Lu, Y., Zhang, Y., Pan, Z.,
Cai, B., et al. (2009). Downregulation of miR-
133 and miR-590 contributes to nicotine-induced
atrial remodelling in canines. Cardiovasc. Res. 83,
465–472. doi: 10.1093/cvr/cvp130
Shi, K. H., Tao, H., Yang, J. J., Wu, J. X., Xu, S. S.,
and Zhan, H. Y. (2013). Role of microRNAs in
atrial fibrillation: new insights and perspectives.
Cell Signal. 25, 2079–2084. doi: 10.1016/j.cellsig.
2013.06.009
Wang, Z., Lu, Y., and Yang, B. (2011). MicroRNAs and
atrial fibrillation: new fundamentals. Cardiovasc.
Res. 89, 710–721. doi: 10.1093/cvr/cvq350
Xiao, J., Liang, D., and Chen, Y. (2011a). The
genetics of atrial fibrillation: from the bench to
the bedside. Annu. Rev. Genomics Hum. Genet.
12, 73–96. doi: 10.1146/annurev-genom-082410-
101515
Xiao, J., Liang, D., Zhang, Y., Liu, Y., Zhang, H.,
Liu, Y., et al. (2011b). MicroRNA expression sig-
nature in atrial fibrillation with mitral steno-
sis. Physiol. Genomics 43, 655–664. doi: 10.1152/
physiolgenomics.00139.2010
Xiao, J., Liang, D., Zhang, H., Liu, Y., Zhang, D., Liu,
Y., et al. (2012). MicroRNA-204 is required for
differentiation of human-derived cardiomyocyte
progenitor cells. J. Mol. Cell. Cardiol. 53, 751–759.
doi: 10.1016/j.yjmcc.2012.08.024
Zhang, Y., Dong, D., and Yang, B. (2011). Atrial
remodeling in atrial fibrillation and association
between microRNA network and atrial fibrillation.
Sci. China Life Sci. 54, 1097–1102. doi: 10.1007/
s11427-011-4241-3
Zhao, Z., Liu, T., Wang, X., and Li, G. (2013).
MicroRNAs as novel antiarrhythmic targets for
atrialfibrillation. Int. J. Cardiol. 168, e135–e137.
doi: 10.1016/j.ijcard.2013.08.014
Conflict of Interest Statement: The authors declare
that the research was conducted in the absence of any
commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 20 February 2014; accepted: 05 April 2014;
published online: 30 April 2014.
Citation: Fu S, Huang L, Wang Y, Li X, Li J and Xiao J
(2014) MicroRNA as a novel player in atrial fibrillation.
Front. Genet. 5:97. doi: 10.3389/fgene.2014.00097
This article was submitted to Epigenomics and
Epigenetics, a section of the journal Frontiers in
Genetics.
Copyright © 2014 Fu, Huang, Wang, Li, Li and Xiao.
This is an open-access article distributed under the
terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s)
or licensor are credited and that the original pub-
lication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with
these terms.
Frontiers in Genetics | Epigenomics and Epigenetics April 2014 | Volume 5 | Article 97 | 2
